Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5004 PK Interaction with Mitiglinide and Pioglitazone in Healthy Participants
NCT07444424Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elecoglipron in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity at Day 70, Area under concentration-curve from time 0 to the last quantifiable concentration at Day 70 and 1 more. Started Mar 2026; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07444424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444424.